This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): PS540446, p38 kinase inhibitor
Description: BMS-582949 is a p38 kinase inhibitor. P38 kinase inhibitors are thought to exert their anti-inflammatory effects by inhibiting the activity of pro-inflammatory cytokines such as tumour necrosis factor-alpha and interleukin-1 beta.
Deal Structure: In December 1997, Bristol-Myers Squibb Company and Pharmacopeia announced the formation of a three-year research collaboration. In collaboration with Bristol-Myers Squibb, Pharmacopeia uses its proprietary ECLiPS and high throughput screening (HTS) technologies to identify and optimize small molecule drug candidates for the agreed upon targets. Additionally, Pharmacopeia provides Bristol-Myers Squibb with combinatorial libraries of novel chemical structures for testing by Bristol-Myers Squibb in its internal research programs.
Under the terms of the agreement, Bristol-Myers Squibb provided Pharmacopeia with an initial up-front payment, annual research funding and milestone payments. Pharmacopeia will receive royalty payments from Bristol-Myers Squibb from the sale of any products generated by the collaboration. Total potential value of the research collaboration, excluding royalties, is approximately $40 million. Additional milestone and royalty payments are possible from...See full deal structure in Biomedtracker
Partners: Ligand Pharmaceuticals, Inc.
Additional information available to subscribers only: